Yuji Mishima

4.0k total citations
94 papers, 2.3k citations indexed

About

Yuji Mishima is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Yuji Mishima has authored 94 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 38 papers in Molecular Biology and 27 papers in Hematology. Recurrent topics in Yuji Mishima's work include Multiple Myeloma Research and Treatments (24 papers), Electrochemical sensors and biosensors (11 papers) and Electrochemical Analysis and Applications (10 papers). Yuji Mishima is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Electrochemical sensors and biosensors (11 papers) and Electrochemical Analysis and Applications (10 papers). Yuji Mishima collaborates with scholars based in Japan, United States and Italy. Yuji Mishima's co-authors include Kiyohiko Hatake, Aldo M. Roccaro, Irene M. Ghobrial, Michele Moschetta, Antonio Sacco, Junko Motonaka, Yasuhito Terui, Kenichi Maruyama, Salomon Manier and Nobuyuki Mizunuma and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yuji Mishima

90 papers receiving 2.3k citations

Peers

Yuji Mishima

ONCOL

HEMAT

IMMUN

Yuhuan Zheng China

Cheng Cheng Zhang United States

Marco Scarsella Italy

Tao Fang China

Emmet McCormack Norway

Jihe Zhao United States

Barbara Muz United States

Brian G. Till United States

Michaela Feuring‐Buske Germany

Yuhuan Zheng China

Yuji Mishima

1.0k ×1.0

966 ×1.0

ONCOL

590 ×1.0

HEMAT

949 ×2.1

IMMUN

255 ×0.6

Citations per year, relative to Yuji Mishima Yuji Mishima (= 1×) peers Yuhuan Zheng

Countries citing papers authored by Yuji Mishima

Since Specialization

Citations

This map shows the geographic impact of Yuji Mishima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuji Mishima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuji Mishima more than expected).

Fields of papers citing papers by Yuji Mishima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuji Mishima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuji Mishima. The network helps show where Yuji Mishima may publish in the future.

Co-authorship network of co-authors of Yuji Mishima

This figure shows the co-authorship network connecting the top 25 collaborators of Yuji Mishima. A scholar is included among the top collaborators of Yuji Mishima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuji Mishima. Yuji Mishima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mishima, Yuji, et al.. (2023). 303 PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma. SHILAP Revista de lepidopterología. A346–A346. 1 indexed citations

Shen, Yu J., Yuji Mishima, Jiantao Shi, et al.. (2020). Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 137(17). 2360–2372. 32 indexed citations

Kurdi, Ahmed T., Siobhan Glavey, Natalie Bezman, et al.. (2018). Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics. 17(7). 1454–1463. 70 indexed citations

Takagi, Satoshi, Shokichi Tsukamoto, Jihye Park, et al.. (2018). Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clinical Cancer Research. 24(10). 2430–2439. 45 indexed citations

Sasaki, Koichi, Daisuke Asai, Daiki Funamoto, et al.. (2018). A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells. MedChemComm. 9(5). 783–788. 6 indexed citations

Mishima, Yuji, Satoshi Matsusaka, Keisho Chìn, et al.. (2017). Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. Targeted Oncology. 12(3). 341–351. 38 indexed citations

Sacco, Antonio, Aldo M. Roccaro, Dong-Dong Ma, et al.. (2016). Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Research. 76(2). 463–471. 41 indexed citations

Maiso, Patricia, Daisy Huynh, Michele Moschetta, et al.. (2015). Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma. Cancer Research. 75(10). 2071–2082. 166 indexed citations

Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations

10.

Mishima, Yuji, Yasuhito Terui, Yuko Mishima, et al.. (2012). High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. International Immunology. 24(8). 477–483. 28 indexed citations

11.

Nakano, Kenji, Takeshi Yuasa, Nao Nishimura, et al.. (2012). Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas. Japanese Journal of Clinical Oncology. 42(8). 697–703. 34 indexed citations

12.

Matsusaka, Satoshi, Mitsukuni Suenaga, Yuji Mishima, et al.. (2011). Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Science. 102(6). 1188–1192. 57 indexed citations

13.

Mishima, Yuji, Natsuhiko Sugimura, Yasuhito Terui, et al.. (2009). An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy. Clinical Cancer Research. 15(10). 3624–3632. 13 indexed citations

14.

Mishima, Yuko, Yasuhito Terui, Yuji Mishima, et al.. (2008). Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Science. 99(11). 2200–2208. 53 indexed citations

15.

Terui, Yasuhito, Yuji Mishima, Kiyotsugu Kojima, et al.. (2007). Antitumor effect of IKKβ inhibitor IMD-0354 on bortezomib-resistant multiple myeloma cells. Molecular Cancer Therapeutics. 6. 1 indexed citations

16.

Mishima, Yuji, et al.. (2007). Continuous treatment of bestatin induces anti‐angiogenic property in endothelial cells. Cancer Science. 98(3). 364–372. 20 indexed citations

17.

Terui, Yasuhito, Takuma Sakurai, Yuko Mishima, et al.. (2005). Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab. Cancer Science. 97(1). 72–79. 54 indexed citations

18.

Mishima, Yuji. (2002). Leukemic Cell-Surface CD13/Aminopeptidase N and Resistance to Apoptosis Mediated by Endothelial Cells. JNCI Journal of the National Cancer Institute. 94(13). 1020–1028. 40 indexed citations

19.

Mori, Masaki, Yasuhito Terui, Masayuki Ikeda, et al.. (1999). β2-Microglobulin Identified as an Apoptosis-Inducing Factor and Its Characterization. Blood. 94(8). 2744–2753. 26 indexed citations

20.

Maruyama, Kenichi, Junko Motonaka, Yuji Mishima, & Yasuo Nakabayashi. (1999). DNA hybridization sensor utilizing [Os(5, 6-dmphen)3]2+ by square wave voltammetry. Nucleic Acids Symposium Series. 42(1). 181–182. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact